Trials / Conditions / Hypogammaglobulinemia

Hypogammaglobulinemia

20 registered clinical trials studyying Hypogammaglobulinemia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections NCT07220915	Octapharma	Phase 3
Recruiting	Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia NCT06976476	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+ NCT05645107	Grifols Therapeutics LLC	Phase 3
Recruiting	Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extensio NCT05678621	Monash University	Phase 2 / Phase 3
Recruiting	Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? NCT05357781	Insel Gruppe AG, University Hospital Bern	—
Completed	Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Pa NCT04502030	Octapharma	Phase 3
Unknown	Immunodeficiency in MS NCT04447937	Advanced Neurosciences Institute	—
Unknown	Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis NCT04283747	Mazandaran University of Medical Sciences	—
Completed	Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients NCT03401268	University Health Network, Toronto	N/A
Completed	Personalized Immunotherapeutic for Antibiotic-resistant Infection NCT02508584	Brigham and Women's Hospital	EARLY_Phase 1
Completed	Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome NCT02231879	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2 / Phase 3
Completed	Post-bypass Prophylactic IVIG in Infants and Neonates NCT02043379	University of Alabama at Birmingham	N/A
Unknown	Investigation of Immune Disorders and Deficiencies NCT01981785	O & O Alpan LLC	—
Completed	Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) NCT01581593	Kedrion S.p.A.	Phase 3
Completed	Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or S NCT01002755	M.D. Anderson Cancer Center	Phase 2
Completed	Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. NCT00278954	Bio Products Laboratory	Phase 3
Completed	Intravenous Immunoglobulin (IVIG) in Lung Transplantation NCT00115778	Columbia University	Phase 2
Completed	Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solutio NCT00161993	Baxalta now part of Shire	Phase 2
Completed	Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients NCT00138697	Prothya Biosolutions	Phase 2 / Phase 3
Completed	Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients NCT00137748	The Cleveland Clinic	Phase 2 / Phase 3